Edwards Lifesciences Corporation

Equities

EW

US28176E1082

Market Closed - Nyse Other stock markets 05:00:02 17/01/2026 HKT			5-day change	1st Jan Change
84.35 ^USD	-0.17%		-0.27%	-1.06%

01-13	Edwards Lifesciences Corporation Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-12-2026 11:15 AM
01-12	UBS Adjusts Price Target on Edwards Lifesciences to $95 From $92, Maintains Neutral Rating	MT

Transcript : Edwards Lifesciences Corporation - Analyst/Investor Day

Published on 12/11/2025 at 05:22 pm HKT - Modified on 12/11/2025 at 09:51 pm HKT

S&P Capital IQ

Presenter Speech
Mark Wilterding (Executives)

Well, good morning, everyone. We really appreciate you all joining us today. Thank you for making the trip out here. For those of you who are in person.

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Edwards Lifesciences Corporation

01-13	Edwards Lifesciences Corporation Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-12-2026 11:15 AM
01-12	UBS Adjusts Price Target on Edwards Lifesciences to $95 From $92, Maintains Neutral Rating	MT
01-12	Independence, Under Review
01-12	North American Morning Briefing : Stock Futures Fall, Gold Hits Record on Fed Concerns -2-	DJ
01-12	Barclays Adjusts Price Target on Edwards Lifesciences to $104 From $103, Maintains Overweight Rating	MT
01-12	Baird Adjusts Price Target on Edwards Lifesciences to $90 From $87, Maintains Neutral Rating	MT
01-12	RxSight Names Mark Wilterding Finance Chief	MT
01-12	Edwards Lifesciences Drops Bid to Acquire JenaValve Technology	MT
01-11	RxSight, Inc. Appoints Mark Wilterding as Chief Financial Officer, Effective January 11, 2026	CI
01-10	Edwards Lifesciences Drops Merger With JenaValve	DJ
01-10	Edwards says co will not acquire Jenavalve	RE
01-10	US FTC wins ruling blocking Edwards Lifesciences' acquisition of JenaValve	RE
01-09	Goldman Sachs Adjusts Price Target on Edwards Lifesciences to $108 From $104, Maintains Buy Rating	MT
01-09	TD Cowen Upgrades Edwards Lifesciences to Buy From Hold, Adjusts Price Target to $97 From $90	MT
01-06	Evercore ISI Adjusts PT on Edwards Lifesciences to $94 From $92, Maintains Outperform Rating	MT
12-23	Edwards Lifesciences Says FDA Approves Valve Replacement System	MT
12-23	FDA approves Edwards Lifesciences' Sapien M3 mitral valve replacement system as first transseptal transcatheter therapy	RE
12-23	FDA Approves Edwards Lifesciences' Sapien M3 Mitral Valve Replacement System as First Transseptal Transcatheter Therapy	CI
12-19	North American Morning Briefing : Stock Futures Up as Investors Bet on Fed Rate Cuts -2-	DJ
12-18	Inflation Took a Chill Pill
12-18	JPMorgan Upgrades Edwards Lifesciences to Overweight From Neutral, Adjusts PT to $100 From $90	MT
12-18	Analyst recommendations: American Express, Merck, Rivian, Albemarle, Micron…
12-17	Canaccord Genuity Adjusts PT on Edwards Lifesciences to $87 From $89, Maintains Hold Rating	MT
12-16	Baird Trims Price Target on Edwards Lifesciences to $87 From $88, Maintains Neutral Rating	MT
12-11	Citigroup Adjusts Edwards Lifesciences Price Target to $101 From $96, Maintains Buy Rating	MT